H. Lundbeck stock
Price history
+65.65% over the period1 year: from kr 34.35 (November 17, 2025) to kr 56.90 (November 16, 2026), +65.65%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 56.90 |
| October 30, 2026 | kr 50.00 |
| September 30, 2026 | kr 42.70 |
| August 31, 2026 | kr 41.80 |
| July 31, 2026 | kr 36.00 |
| June 30, 2026 | kr 36.60 |
| May 29, 2026 | kr 36.80 |
| April 30, 2026 | kr 35.40 |
| March 31, 2026 | kr 33.40 |
| February 27, 2026 | kr 34.80 |
| January 30, 2026 | kr 36.85 |
| December 30, 2025 | kr 36.20 |
| November 28, 2025 | kr 35.00 |
| November 17, 2025 | kr 34.35 |
At a glance
The company
Research, develop, manufacture and commercialize pharmaceuticals for psychiatric and neurological disorders
Latest results
Quarter to June 30, 2026 · EPS kr 1.16
Next event
TickerLandia's take on H. Lundbeck
- Pricier than usual relative to earnings: P/E on the latest fiscal year 18 vs a median of 12 over its last 4 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 14 vs 19 (−26%) in a group of 11.
- Strong point: Market momentum (97/100 in its group). Weak point: Dividend (37/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.23% from the 52-week high
TickerLandia Fingerprint: H. Lundbeck
Compared with similar companies: very strong momentum.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow21
How much it costs relative to what it produces.
Metric Value Position in group Price/book 2.04 32 Price/sales 2.20 28 EV/EBITDA 7.61 7 P/E (trailing 12 months) 14.2 16 Profitabilityhigh67
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 24.4% 71 Gross margin 81.2% 86 Net margin 15.7% 60 ROE 15.4% 63 ROA 7.5% 58 Earnings stabilityaverage53
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.9% 43 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage53
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +17.40% 69 Average revenue growth (3 years) +10.52% 59 Revenue growth (year over year) +5.20% 30 Financial strengthaverage45
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.07 47 Interest coverage 11.4 45 Debt/equitycounts in reverse: lower means more financial strength 0.31 57 Current ratio 1.43 32 Dividendlow37
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 4 years 18 Dividend yield 2.0% 60 Payout ratio 28.1% 34 Market momentumvery strong97
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +63.71% 94 Distance from 200-day average +50.93% 99 Riskaverage53
How much the price swings.
Metric Value Position in group Volatility (60 days) 34.2% 73 Maximum drawdown (12 months) 20.2% 34
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
H. Lundbeck is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), H. Lundbeck's P/E today is 17.7, above the median of its last 4 fiscal years (11.8; between 10.5 and 12.4 from 2022 to 2025). H. Lundbeck's P/E (trailing 12 months): 14.2, −26% against the median of a group of 11 similar companies (19.4).
Compared with 11 similar companies
| Metric | H. Lundbeck | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 14.2 | Low | |
| Operating margin | 24.4% | High | |
| ROE | 15.4% | Middle | |
| Debt/equity | 0.31 | Middle | |
| Price/book | 2.04 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: H. Lundbeck. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 6.46B
Latest quarter · Q2 2026
Net income
kr 1.15B
Latest quarter · Q2 2026
Quarterly net margin
17.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 57.74B
- P/E
- 14.2
- EPS
- kr 4.09
- Volume
- 40.31K
- Daily trading
- €523.14K
- Dividend yield
- 2.02%
- Last ex-dividend on March 19, 2026
How H. Lundbeck is changing
All resultsRevenue grew 6.9% a year on average over the last 5 years
Operating margin rose from 15.6% to 23.9%
Profits turn into cash: free cash flow equal to 130% of net income
Returns
H. Lundbeck returns with dividends
kr 1,000 invested in H. Lundbeck 3 years ago, on November 16, 2023, would be worth kr 2,082 today with dividends reinvested: +108.25% in total, +27.69% per year. On price alone it would be kr 1,904 (+90.43%).
| Period | H. Lundbeck | kr 1,000 becomes |
|---|---|---|
| 1 month | +26.30% | kr 1,263 |
| 6 months | +58.06% | kr 1,581 |
| Year to date | +57.18% | kr 1,572 |
| 1 year | +71.34% | kr 1,713 |
| 3 years | +108.25% | kr 2,082 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
H. Lundbeck: technical analysis
H. Lundbeck is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.5% below its all-time closing high (kr 59.60, November 11, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 71
- Above 70: a strong rise in a short time
- vs 200-session average
- +47.19%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since October 20, 2026
Support and resistance
Price areas where H. Lundbeck has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last pricekr 56.90
- Supportkr 44.63−21.56%3 touches, last on September 28, 2026
- Supportkr 37.44−34.20%4 touches, last on July 3, 2026
- Supportkr 36.23−36.33%9 touches, last on July 31, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 34.7%
- Largest fall in the last year
- −20.18%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
H. Lundbeck and its competitors
Patients with psychiatric and neurological disorders in Europe, the United States and other international markets are served by H. Lundbeck A/S, which researches, develops, manufactures and commercializes pharmaceuticals for these conditions, including schizophrenia, bipolar I disorder, depression, migraine, epilepsy, dementia and Parkinson's disease. Its products include Abilify Maintena, Brintellix, Rexulti, Vyepti and Azilect. Its pipeline includes Eptinezumab in phase 3 testing for cluster headache and bexicaserin in phase 3 for developmental and epileptic encephalopathies.
- Headquarters
- Valby, Denmark
- Employees
- 5,000
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| H. LundbeckHLUN.A | $8.54B | 24.4% | 14.2 | +58.06% |
| IpsenIPN | $15.16B | 27.4% | 26.9 | +0.60% |
| Swedish Orphan BiovitrumSOBI | $16.42B | 30.9% | 25.0 | +8.39% |
| Laboratorios Farmaceuticos RoviROVI | $3.57B | 19.5% | 17.4 | +18.15% |
| Siegfried HoldingSFZN | $3.67B | 16.7% | 18.0 | −11.22% |
| AlmirallALM | $2.57B | 13.3% | 32.4 | −5.83% |
Same industry or related industries, similar size. Compare H. Lundbeck with its competitors · Full profile
